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We have adopted a conservative attitude to the treatment of complete heart block and all patients were treated medically except for two who were paced electrically. Anterior infarction as a cause of heart block was associated with a higher mortality (78%) than inferior infarction (36%). These figures compare adequately with those of Lassers and Julian (1968) and of Scott et al. (1967) who paced much more frequently than we have done. We are not convinced, however, that our conservative approach is the correct one.
We conclude that a shorter period in hospital and more rapid mobilization than are normally practised are justified. By so doing beds in coronary care units are made available for patients who are at the highest risk within the first few hours and days after acute myocardial infarction. 
Introduction
Tamoxifen is the trans-isomer of 1 (p-p-dimethylaminoethoxyphenyl)-l, 2-diphenylbut-1-ene. In several but not all mammalian species it is a potent anti-oestrogen. It is thought to act by blocking oestrogen receptors. Nevertheless, very high dosage in rats has an oestrogenic effect while low dosage is antioestrogenic. The first clinical use of an anti-oestrogen for breast carcinoma was described by Kistner and Smith (1960) and further trials were described by Herbst et al. (1964) . The only published report on the use of tamoxifen is that of Cole et al. (1971) . Patients and Methods Sixty-eight patients were admitted to the trial. They all had either very advanced primary carcinoma of the breast, recurrence on the chest wall, or soft tissue metastases which could be measured. Other metastases might have been present but these did not affect admission to the trial. In most patients a histological diagnosis was available but in a few patients with very advanced primary disease a biopsy specimen had not been obtained. No patient was admitted to the trial unless there had been a lapse of at least three months from previous treatment with hormones or cytotoxic drugs and from the menopause, either natural or artificial.
Patients were divided into four groups depending on the presence or absence of blood-borne metastases and whether more or less than five years had elapsed from the menopause. For each group a previously prepared randomization table was used to allocate a patient to low or high dose treatment so that the number receiving low or high dosage in each group would be similar. The dosage of tamoxifen (ICI 46474) was either 10 mg or 20 mg twice daily.
During the first six months of treatment patients were seen at least monthly, and thereafter some were allowed a two-month interval between visits. At the beginning of the trial all patients had haematological and biochemical investigations at least every month but when normal results had been obtained regularly for six months the interval was lengthened.
Symptomatic Side Effects.-The incidence of symptoms attributable to the drug is shown in table I. When a patient had more than one symptom each has been noted so that the number of symptoms recorded exceeds the number of patients If the figures for definite and partial responses are added together the total response rates are 60% for low dosage and 77% for high dosage.
There was no evidence that the drug had any effect on the bone marrow, liver function, or blood calcium levels. The incidence of symptomatic side effects was almost the same at either dose level, and the particular advantages of this drug were the absence of virilization or fluid retention and the fact that injections were not required.
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